In Darwinian terms, survival isn’t a matter of being the biggest, the fastest, or the strongest of the species, but instead ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

At Fast Company and Johns Hopkins University's World Changing Ideas Summit in November, leaders shared what's top of mind for ...

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

Vertical integration for CDMOs in manufacturing ADCs offers an opportunity to reduce costs and create a more resilient supply ...

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive ...

Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...